12 Apr 2021
MedSource and PSR Orphan Experts rebrand to Ergomed

Today, we are delighted to share the exciting news that following the successful integration of both PSR Orphan Experts and MedSource we will be aligning all our CRO businesses under the Ergomed name.

In December, we shared the news of the acquisition of MedSource by Ergomed plc, an Award-winning, oncology-focused U.S.-based CRO that allowed us to expand our services significantly. PSR Orphan Experts has been a part of Ergomed since 2017, when Ergomed acquired PSR Group BV, a specialist Orphan Drug CRO, to further enhance our rare disease specialty expertise.

Gordana Tonković, Ergomed President, CRO, said: “The mergers’ combined strength provides expanded services with strong expertise in oncology and rare diseases trials, global CRO coverage across the U.S. and Europe, and access to additional solutions in pharmacovigilance, regulatory, medical information, and medical services, all under one organization for better and faster trials.”

For more than 24 years, Ergomed has provided specialized services to the pharmaceutical industry spanning all phases of clinical trials, pre-and post-approval pharmacovigilance, and medical information. 

Should you have any questions, please contact us via info@ergomedplc.com 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all clinical development phases, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO), with a strong heritage in the development of drugs in rare diseases and oncology. For further information, visit https://ergomedplc.com